CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada's sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES,
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central
12-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 "RESCUE" registrational program remains on
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
